Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Post by HomerAndCompanyon Mar 09, 2023 10:45am
312 Views
Post# 35328071

@2022 end 5% month-over-month revenue increase from 35 sites

@2022 end 5% month-over-month revenue increase from 35 sitesLatest quarter 2022 was all about growing recurring revenue with TULSA-PRO treatments in USA. The revenue growth rate reached 5% per month. No capital equipment sales last Q due to on-going COVID issues in China & Japan.

They expect the 5% per month revenue growth rate for TULSA to be maintaned or likely increase in 2023 as urologiets gain experience and more sites are installed. The time required to install new sites is expected to come down significantly.

Armed now with data from both 2021 and 2022 they will be applying for permanent CPT reimbursement. The result of that applicaition should be known in the first days of June, 2023



<< Previous
Bullboard Posts
Next >>